[Erdheim-Chester disease (ECD), an inflammatory myeloid neoplasia].

[Erdheim-Chester disease (ECD), an inflammatory myeloid neoplasia]. Presse Med. 2016 May 24; Authors: Haroche J, Papo M, Cohen-Aubart F, Charlotte F, Maksud P, Grenier PA, Cluzel P, Mathian A, Emile JF, Amoura Z Abstract In a compatible clinico-radiological setting, the diagnosis of Erdheim-Chester disease (ECD) involves the analysis of histiocytes in tissue biopsies: they are typically foamy and CD68+ CD1a, whereas in Langerhans cell histiocytosis (LCH) they are CD68+ CD1a+. Overlap forms of histiocytoses are frequent. Technetium bone scintigraphy showing nearly constant tracer uptake by the long bones is highly suggestive of ECD and a 'hairy kidney' appearance on abdominal CT scan is observed in more than half ECD cases. CNS involvement is a strong prognostic factor and an independent predictor of death in cases of ECD. Optimal initial therapy for ECD appears to be administration of IFN-α (and/or pegylated IFN-α) and prolonged treatment significantly improves survival; however, tolerance may be poor. Best alternative therapies are anakinra, mainly effective for mild forms of the disease, infliximab, and sirolimus. Cases of ECD present with strong systemic immune activation, involving IFN-α, IL-1/IL1-RA, IL-6, IL-12, and MCP-1, consistent with the systemic immune Th-1-oriented disturbance associated with the disease. Between 57 and 75% of ECD patients carry the BRAF(V600E) mutation, an activating mutation of the proto-oncogene BR...
Source: Presse Medicale - Category: Journals (General) Authors: Tags: Presse Med Source Type: research